Who owns BOLD - AUDENTES THERAPEUTICS INC - COM based on 13F filings?

Open this security page to review the newest available 13F ownership history, top reported holders, and period-by-period changes.

AUDENTES THERAPEUTICS INC - COM (BOLD) Institutional Ownership

Q: What is CUSIP 05070R104?

CUSIP 05070R104 is the security identifier used in SEC filing datasets for BOLD - AUDENTES THERAPEUTICS INC - COM.

CUSIP: 05070R104

13F Institutional Holders and Ownership History from Q3 2016 to Q1 2020

Type / Class: Equity / COM
Symbol: BOLD on Nasdaq

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Investment Quick Answers

What is CUSIP 05070R104?
CUSIP 05070R104 identifies BOLD - AUDENTES THERAPEUTICS INC - COM in SEC 13F datasets.

Where can I see the latest institutional holders?
Use the ownership history tables below to review the newest available institutional filing periods.

Continue Investment Research

Latest 13F filings for new institutional portfolio disclosures.
Latest Schedule 13D/13G reports for activist and beneficial ownership updates.
Latest 10-Q/10-K reports to cross-check issuer fundamentals.
Recent insider transactions for management buying/selling context.
SEC investors directory and top value investors for manager-level discovery.
All institutional ownership pages to compare adjacent CUSIP pages.

Recent Quarterly Holder Reports

Open recent reporting periods for CUSIP 05070R104:

Q1 2020 (0 holders) Q4 2019 (185 holders) Q3 2019 (142 holders) Q2 2019 (145 holders) Q1 2019 (137 holders) Q4 2018 (125 holders) Q3 2018 (113 holders) Q2 2018 (121 holders) Q1 2018 (112 holders) Q4 2017 (86 holders)

Institutional Holders of AUDENTES THERAPEUTICS INC - COM (BOLD) across Reporting Periods

Period	Reported Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price (Median)	Investors
2020 Q1	0	$0	-$2,559,723,450	$0	$0		0
2019 Q4	43,024,345	$2,574,456,027	+$256,265,768	$80,549,000	$10,083,000	$59.84	185
2019 Q3	44,600,296	$1,252,786,822	+$1,632,937	$1,472,000	$1,096,000	$28.09	142
2019 Q2	44,668,919	$1,691,004,753	+$93,116,243	$1,844,000	$10,154,000	$37.86	145
2019 Q1	43,738,394	$1,706,572,305	+$30,876,825	$807,000	$2,832,000	$39.02	137
2018 Q4	43,113,813	$919,169,824	+$134,248,878	$429,000	$1,017,000	$21.32	125
2018 Q3	36,129,389	$1,430,324,014	+$4,656,744	$1,951,000	$2,807,000	$39.59	113
2018 Q2	36,046,535	$1,377,317,197	+$59,316,112	$4,184,000	$1,750,000	$38.21	121
2018 Q1	34,677,880	$1,042,053,309	+$263,768,588	$2,374,000	$2,092,000	$30.05	112
2017 Q4	24,559,929	$767,585,500	+$32,219,505			$31.25	86
2017 Q3	23,564,935	$660,436,938	+$64,800,303			$28.01	79
2017 Q2	21,394,154	$409,288,640	+$106,420,530			$19.13	69
2017 Q1	15,960,466	$271,964,916	+$22,292,094			$17.04	57
2016 Q4	15,502,801	$282,793,160	+$1,573,670			$18.27	55
2016 Q3	15,421,847	$272,037,347	+$272,037,347			$17.81	49